Author:
Barth C., ,Soares M.,Toffart A. C.,Timsit J. F.,Burghi G.,Irrazabal C.,Pattison N.,Tobar E.,Almeida B. F.,Silva U. V.,Azevedo L. C.,Rabbat A.,Lamer C.,Parrot A.,Souza-Dantas V. C.,Wallet F.,Blot F.,Bourdin G.,Piras C.,Delemazure J.,Durand M.,Salluh J.,Azoulay E.,Lemiale Virginie
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference38 articles.
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr , accessed on 01/09/2014.
2. Hamard C, Ruppert A-M, Lavole A, Rozensztajn N, Antoine M, Cadranel J, et al. News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy). Ann Pathol. 2016;36(1):63–72.
3. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirol Carlton Vic. 2016;21(5):821–33.
4. Schapira DV, Studnicki J, Bradham DD, Wolff P, Jarrett A. Intensive care, survival, and expense of treating critically ill cancer patients. JAMA. 1993;269(6):783–6.
5. Garrouste-Orgeas M, Montuclard L, Timsit J-F, Reignier J, Desmettre T, Karoubi P, et al. Predictors of intensive care unit refusal in French intensive care units: a multiple-center study. Crit Care Med. 2005;33(4):750–5.